Scrip
Sepracor files anti-epileptic Stedesa in US
02 April 2009
Katie McQue
Please Login to read the full article.
02 April 2009
Katie McQue
Sepracor has filed its anti-epileptic Stedesa (eslicarbazepine acetate) with the US FDA as a once-daily adjunctive therapy, in doses of 800mg and 1,200mg, for the maintenance treatment of partial onset seizures in adults.
"Clinical studies have indicated that Stedesa has the potential to...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
SCIENCE
- Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial
- Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial
EVENTS
Today
Berlin, Germany
Today
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
